SCHEMBL5373499

SCHEMBL5373499

O=C(O)N1CC=C(c2cccc(F)c2)CC1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.55
LMNA P02545 2/20 0.55
HTT P42858 2/20 0.55
NPSR1 Q6W5P4 1/20 0.55
ALDH1A1 P00352 8/20 0.52
SMN1; SMN2 Q16637 3/20 0.52
ALOX15 P16050 3/20 0.52
NPC1 O15118 2/20 0.52
RAB9A P51151 2/20 0.52
HPGD P15428 2/20 0.52
CASP3 P42574 1/20 0.52
SENP8 Q96LD8 1/20 0.52
SENP7 Q9BQF6 1/20 0.52
SENP6 Q9GZR1 1/20 0.52
TSHR P16473 2/20 0.51
MEN1 O00255 2/20 0.51
KMT2A Q03164 2/20 0.51
NAMPT P43490 1/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
KDM4E B2RXH2 3/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27791860 0.85 MAPT (0.43) MAPTLMNAHTTNPSR1ALDH1A1
SCHEMBL5959136 0.85 ALDH1A1 (0.57) MAPTLMNAHTTALDH1A1SMN1; SMN2
SCHEMBL2241959 0.85 ALDH1A1 (0.67) MAPTLMNAHTTALDH1A1SMN1; SMN2
SCHEMBL4864624 0.84 ALDH1A1 (0.52) MAPTLMNAHTTALDH1A1SMN1; SMN2
SCHEMBL16113804 0.84 ALDH1A1 (0.52) MAPTLMNAHTTALDH1A1SMN1; SMN2
SCHEMBL4602817 0.83 ALDH1A1 (0.66) MAPTLMNAHTTNPSR1ALDH1A1
SCHEMBL3993976 0.83 ALDH1A1 (0.51) MAPTLMNAHTTALDH1A1SMN1; SMN2
SCHEMBL901957 0.83 ALDH1A1 (0.51) MAPTLMNAHTTALDH1A1SMN1; SMN2
SCHEMBL16496703 0.83 ALDH1A1 (0.52) MAPTLMNAHTTNPSR1ALDH1A1
SCHEMBL2930491 0.82 CCR2 (0.51) MAPTLMNAHTTALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1714961-B1 INDAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORP (JP) 2015-12-09 EP claimed
US-20070173537-A1 Indazole compound and pharmaceutical use thereof MITSUBISHI PHARMA CORPORATION (JP) 2007-07-26 US claimed
EP-1714961-A1 INDAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF Mitsubishi Pharma Corporation (JP) 2006-10-25 EP claimed
EP-1714961-B1 INDAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORP (JP) 2015-12-09 EP disclosed
US-20070173537-A1 Indazole compound and pharmaceutical use thereof MITSUBISHI PHARMA CORPORATION (JP) 2007-07-26 US disclosed
EP-1714961-A1 INDAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF Mitsubishi Pharma Corporation (JP) 2006-10-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070173537-A1 Indazole compound and pharmaceutical use thereof CYP3A5, CYP3A43, TP53 MAPT 593/4885LMNA 3390/4885HTT 1929/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.